Tissue & cell · 2026
Overcoming osimertinib resistance in NSCLC: The role of Notch1 pathway inhibition by berberine.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Xiaozhen, Wen Xia, Fu Jiajia
Аннотация
BACKGROUND: Resistance acquired during treatment with third-generation EGFR-TKIs, including osimertinib, continues to pose a significant obstacle in the management of advanced non-small cell lung cancer (NSCLC). Dysregulation of the Notch1 signaling pathway plays a critical role in tumor development as well as therapeutic resistance. Berberine (BER), a naturally derived bioactive compound, has been reported to exert diverse antitumor effects across multiple cancer types.
METHODS: We investigated Notch1 signaling in osimertinib-resistant NSCLC cells and assessed the effects of combined berberine and osimertinib treatment on epithelial-mesenchymal transition (EMT) and drug sensitivity.
RESULTS: Aberrant Notch1 activation promoted EMT and contributed to osimertinib resistance. Berberine inhibited Notch1 signaling, reversed EMT in resistant cells, and restored sensitivity to osimertinib with minimal toxicity.
CONCLUSION: Berberine overcomes osimertinib resistance by targeting the Notch1 pathway and reversing EMT, providing a novel strategy to enhance EGFR-TKI efficacy in NSCLC and supporting integration of traditional Chinese medicine with targeted therapies.
METHODS: We investigated Notch1 signaling in osimertinib-resistant NSCLC cells and assessed the effects of combined berberine and osimertinib treatment on epithelial-mesenchymal transition (EMT) and drug sensitivity.
RESULTS: Aberrant Notch1 activation promoted EMT and contributed to osimertinib resistance. Berberine inhibited Notch1 signaling, reversed EMT in resistant cells, and restored sensitivity to osimertinib with minimal toxicity.
CONCLUSION: Berberine overcomes osimertinib resistance by targeting the Notch1 pathway and reversing EMT, providing a novel strategy to enhance EGFR-TKI efficacy in NSCLC and supporting integration of traditional Chinese medicine with targeted therapies.